2,061
Views
37
CrossRef citations to date
0
Altmetric
Editorial

Could the Ebola virus matrix protein VP40 be a drug target?

Bibliography

  • Blaney JE, Marzi A, Willet M, et al. Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine. PLoS Pathog 2013;9:e1003389
  • Johansen LM, Brannan JM, Delos SE, et al. FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med 2013;5:190ra79
  • Zhang AP, Bornholdt ZA, Liu T, et al. The ebola virus interferon antagonist VP24 directly binds STAT1 and has a novel, pyramidal fold. PLoS Pathog 2012;8:e1002550
  • Cote M, Misasi J, Ren T, et al. Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature 2011;477:344-8
  • Chang J, Warren TK, Zhao K, et al. Small molecule inhibitors of ER alpha-glucosidases are active against multiple hemorrhagic fever viruses. Antiviral Res 2013;98:432-40
  • Warren TK, Warfield KL, Wells J, et al. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat Med 2010;16:991-4
  • Geisbert TW, Lee AC, Robbins M, et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 2010;375:1896-905
  • Fabozzi G, Nabel CS, Dolan MA, et al. Ebola proteins suppress the effects of small interfering RNA by direct interaction with the mammalian RNA interference pathway. J Virol 2011;85:2512-23
  • Pettitt J, Zeitlin L, Kim do H, et al. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci Transl Med 2013;5:199ra113
  • Qiu X, Alimonti JB, Melito PL, et al. Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies. Clin Immunol 2011;141:218-27
  • Garcia M, Cooper A, Shi W, et al. Productive replication of Ebola virus is regulated by the c-Abl1 tyrosine kinase. Sci Transl Med 2012;4:123ra24
  • Kolokolstov AA, Adhikary S, Garver J, et al. Inhibition of Lassa virus and Ebola virus infection in host cells treated with the kinase inhibitors genistein and tyrophostin. Arch Virol 2012;157:121-7
  • Geisbert TW, Jahrling PB. Differentiation of filoviruses by electron microscopy. Virus Res 1995;39:129-50
  • Noda T, Sagara H, Suzuki E, et al. Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J Virol 2002;76:4855-65
  • Yadav SS, Wilson SJ, Bieniasz PD. A facile quantitative assay for viral particle genesis reveals cooperativity in virion assembly and saturation of an antiviral protein. Virology 2012;429:155-62
  • Liu Y, Lee MS, Olson MA, et al. Bimolecular complementation to visualize filovirus VP40-host complexes in live mammalian cells: toward the identification of budding inhibitors. Adv Virol 2011;2011:341816
  • Bornholdt ZA, Noda T, Abelson DM, et al. Structural rearrangement of Ebola virus VP40 begets multiple functions in the viral life cycle. Cell 2013;154:763-74
  • Dessen A, Volchkov V, Dolnik O, et al. Crystal structure of the matrix protein VP40 from Ebola virus. EMBO J 2000;19:4228-36
  • Hoenen T, Biedenkopf N, Zielecki F, et al. Oligomerization of Ebola virus VP40 is essential for particle morphogenesis and regulation of viral transcription. J Virol 2010;84:7053-63
  • Scianimanico S, Schoehn G, Timmins J, et al. Membrane association induces a conformational change in the Ebola virus matrix protein. EMBO J 2000;19:6732-41
  • Soni SP, Adu-Gyamfi E, Yong SS, et al. The Ebola virus matrix protein deeply penetrates the plasma membrane: an important step in viral egress. Biophys J 2013;104:1940-9
  • Gomis-Ruth FX, Dessen A, Timmins J, et al. The matrix protein VP40 from Ebola virus octamerizes into pore-like structures with specific RNA binding properties. Structure 2003;11:423-33
  • Adu-Gyamfi E, Soni SP, Xue Y, et al. The Ebola virus matrix protein penetrates into the plasma membrane: a key step in viral protein 40 (VP40) oligomerization and viral egress. J Biol Chem 2013;288:5779-89
  • Mim C, Unger VM. Membrane curvature and its generation by BAR proteins. Trends Biochem Sci 2012;37:526-33
  • Miao B, Skidan I, Yang J, et al. Small molecule inhibition of phosphatidylinositol-3,4,5-triphosphate (PIP3) binding to pleckstrin homology domains. Proc Natl Acad Sci USA 2010;107:20126-31
  • Tamilvanan T, Hopper W. High-throughput virtual screening and docking studies of matrix protein VP40 of ebola virus. Bioinformation 2013;9:286-92
  • Hogue IB, Llewellyn GN, Ono A. Dynamic association between HIV-1 Gag and membrane domains. Mol Biol Int 2012;2012:979765
  • Ternois F, Sticht J, Duquerroy S, et al. The HIV-1 capsid protein C-terminal domain in complex with a viral assembly inhibitor. Nat Struct Mol Biol 2005;12:678-82
  • Matyas GR, Wieczorek L, Bansal D, et al. Inhibition of HIV-1 infection of peripheral blood mononuclear cells by a monoclonal antibody that binds to phosphoinositides and induces secretion of β-chemokines. Biochem Biophys Res Commun 2010;402:808-12
  • Vieria CR, Munoz-Olaya JM, Sot J, et al. Dihydrosphingomyelin impairs HIV-1 infection by rigidifying liquid-ordered membrane domains. Chem Biol 2010;17:766-75

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.